Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein

被引：30

作者：

Backes, JM

Gibson, CA

机构：

[1] Univ Kansas, Med Ctr,Sch Pharm, Dept Pharm Practice, Lipid Atherosclerosis Metab & LDL Apheresis Ctr, Kansas City, KS 66160 USA

[2] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS USA

来源：

ANNALS OF PHARMACOTHERAPY | 2005年 / 39卷 / 03期

关键词：

fibrates; low-density lipoprotein; niacin; small-dense; statins;

D O I：

10.1345/aph.1E322

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C). DATA SOURCES: Literature was obtained from MEDLINE (1989-September 2004) and references of selected articles. Key search terms included small-dense LDL-C and lipid-lowering drug therapy. DATA SYNTHESIS: Statins, fibrates, and niacin have demonstrated favorable effects on sdLDL-C, especially among patients with mixed dyslipidemia or hypertriglyceridemia. These effects include a reduction of sdLDL-C and/or a shift to the larger, less atherogenic LDL-C. CONCLUSIONS: Data suggest that statins, fibrates, and niacin are effective at reducing concentrations of sdLDL-C and possibly normalizing LDL-C subclasses.

引用

页码：523 / 526

页数：4

共 25 条

[1] Use of niacin, statins, and resins in patients with combined hyperlipidemia [J].

Brown, BG ;

Zambon, A ;

Poulin, D ;

Rocha, A ;

Maher, VMG ;

Davis, JW ;

Albers, JJ ;

Brunzell, JD .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (4A) :52B-59B

[2] Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses [J].

Calabresi, L ;

Donati, D ;

Pazzucconi, F ;

Sirtori, CR ;

Franceschini, G .

ATHEROSCLEROSIS, 2000, 148 (02) :387-396

[3]

Chapman MJ, 1998, EUR HEART J, V19, pA24

[4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[5] Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates [J].

Forster, LF ;

Stewart, G ;

Bedford, D ;

Stewart, JP ;

Rogers, E ;

Shepherd, J ;

Packard, CJ ;

Caslake, MJ .

ATHEROSCLEROSIS, 2002, 164 (01) :129-145

[6] Effects of Atorvastatin versus Fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia [J].

Frost, RJA ;

Otto, C ;

Geiss, HC ;

Schwandt, P ;

Parhofer, KG .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (01) :44-48

[7] ROLE OF PLASMA TRIGLYCERIDE IN THE REGULATION OF PLASMA LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTIONS - RELATIVE CONTRIBUTION OF SMALL, DENSE LDL TO CORONARY HEART-DISEASE RISK [J].

GRIFFIN, BA ;

FREEMAN, DJ ;

TAIT, GW ;

THOMSON, J ;

CASLAKE, MJ ;

PACKARD, CJ ;

SHEPHERD, J .

ATHEROSCLEROSIS, 1994, 106 (02) :241-253

[8] Small LDL, atherogenic dyslipidemia, and the metabolic syndrome [J].

Grundy, SM .

CIRCULATION, 1997, 95 (01) :1-4

[9] Action of atorvastatin in combined hyperlipidemia - Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles [J].

Guerin, M ;

Lassel, TS ;

Le Goff, W ;

Farnier, M ;

Chapman, MJ .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :189-197

[10] Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux [J].

Guerin, M ;

Egger, P ;

Soudant, C ;

Le Goff, W ;

van Tol, A ;

Dupuis, R ;

Chapman, MJ .

ATHEROSCLEROSIS, 2002, 163 (02) :287-296

← 1 2 3 →